Trial record 3 of 3 for:
Agili-C
Agili-C™ Implant Performance Evaluation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03299959 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 3, 2017
Last Update Posted : March 10, 2022
|
Sponsor:
Cartiheal (2009) Ltd
Information provided by (Responsible Party):
Cartiheal (2009) Ltd
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The current study compares the efficacy and safety of the Agili-C implant to Surgical Standard of Care treatment in patients suffering from joint surface lesions of the knee. The patient population is heterogeneous, involving different kinds of joint surface lesions: focal cartilage lesions, osteochondral defects and mild to moderate osteoarthritis, including multiple defects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cartilage or Osteochondral Defects in the Knee Up to Moderate Osteoarthritis | Device: Agili-C implant Procedure: SSOC | Not Applicable |
This is a prospective, multicenter, open-label, randomized, and controlled trial of Agili-C™ vs. SSOC for the repair of joint surface lesions.
Follow-up visits will be performed at 2 weeks and at 3, 6, 12, 18 and 24 months post-procedure to evaluate the patient's knee condition and clinical health. The following questionnaires: KOOS, IKDC Knee Examination Form 2000, IKDC Subjective Knee Evaluation , SF-12 Health Survey, Tegner Activity Score will be completed at baseline and at 6, 12, 18 and 24 months. Anterior-Posterior (A/P) and Lateral knee X-rays will be taken at 2 weeks and at 6, 12, 18 and 24 months post procedure. MRI according to specific protocol will be performed at 12 and 24 months.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 251 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Open-label Randomized Controlled Trial |
| Masking: | None (Open Label) |
| Masking Description: | Open-Label, adaptive design with interim analyses |
| Primary Purpose: | Treatment |
| Official Title: | A Prospective Multicenter Open-label Randomized Controlled Trial of Agili-C™ vs. Surgical Standard of Care (SSOC) for the Treatment of Joint Surface Lesions of the Knee |
| Actual Study Start Date : | September 5, 2017 |
| Actual Primary Completion Date : | September 30, 2021 |
| Estimated Study Completion Date : | January 1, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Osteoarthritis
MedlinePlus related topics:
Osteoarthritis
| Arm | Intervention/treatment |
|---|---|
| Experimental: Agili-C |
Device: Agili-C implant
Agili-C implant |
| Active Comparator: Surgical Standard of Care (SSOC) |
Procedure: SSOC
microfracture and/or debridement |
Primary Outcome Measures :
- KOOS Score [ Time Frame: Preoperative until 2 years postoperatively ]Knee Injury and Osteoarthritis Outcome Score (KOOS)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- 21 -75 years
- Up to 3 treatable joint surface lesion(s), ICRS Grade III or above, on the femoral condyles and/or trochlea
- Symptomatic total treatable area 1-7 cm2. Asymptomatic lesions will not be included in the calculation
- Must be physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits
- Signed and dated the IRB/Ethics Committee approved Informed Consent Form and HIPPA (if applicable)
- Non-responsive to physical therapy for at least 3-4 weeks
Exclusion Criteria:
- KOOS Pain Subscale score at baseline is less than 20 or more than 65 (scale: maximum pain =0, pain free =100)
- Bony defect depth deeper than 8mm, according to baseline MRI/X-ray/arthroscopy
- Articular cartilage lesions in the tibia or the patella, ICRS grades IVa or above
- Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading
- Significant instability of the index knee according to IKDC Knee Examination Form 2000, Grade C (abnormal) or D (severely abnormal)
- Malalignment more than 8 degrees varus OR 8 degrees valgus according to standing X-ray
- Lack of functional remaining meniscus, at least 5mm rim at the end of the procedure
- Meniscal transplantation in the past 6 months
- Any known tumor of the index knee
- Any known history of intra-articular or osseous infection of the index knee
- Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, and provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known systemic cartilage and/or bone disorder, such as but not limited to, osteoporosis, chondrodysplasia or osteogenesis imperfecta
- Body Mass Index (BMI) > 35
- Chemotherapy in the past 12 months
- Any previous surgical cartilage treatment (such as: microfracture, ACI, OATS, etc.) in the index knee within the last 6 months
- Any previous ligamentous repair or malalignment correction in the index knee within the last 6 months
- History of allergic reaction or intolerance of materials containing calcium carbonate or hyaluronate
- Patient who is pregnant or intends to become pregnant during the study
- History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies
- Known substance or alcohol abuse
- Participation in other clinical trials within 60 days prior to the study or concurrent with the study
- Known insulin dependent diabetes mellitus
- Unable to undergo either MRI or X-ray
- Use of anticoagulation medication or antiaggregant medication; however up to 100 mg Acetylsalicylic acid (ASA) daily is allowed
- Previous intra-articular steroid injection within the last 1 month
- Prisoners
- Uncontained lesion - Lack of vital bone wall, at least 2mm thick, completely surrounding the lesion - based on MRI/X-ray/arthroscopy
- Inability to position the implant 2mm recessed relative to the articular surface - based on MRI/X-ray/arthroscopy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03299959
Locations
Show 26 study locations
Sponsors and Collaborators
Cartiheal (2009) Ltd
Investigators
| Principal Investigator: | Elizaveta Kon, MD | Istituto Clinico Humanitas, Via A. Manzoni 56, Rozzano, Milano, Italy |
| Responsible Party: | Cartiheal (2009) Ltd |
| ClinicalTrials.gov Identifier: | NCT03299959 |
| Other Study ID Numbers: |
CLN0021 |
| First Posted: | October 3, 2017 Key Record Dates |
| Last Update Posted: | March 10, 2022 |
| Last Verified: | July 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |